Sulfur Burps on Wegovy (Semaglutide 2.4 mg): Week-by-Week Timeline of What to Expect

What the Wegovy label records about burping

The Wegovy 2.4 mg injection safety results pool three placebo-controlled trials of up to 68 weeks, with 2,116 adults on Wegovy and 1,261 on placebo. In that pooled group, eructation was reported by 7% on Wegovy versus under 1% on placebo [1]. Eructation also appears in the label's list of the most common adverse reactions, meaning those reported by 5% or more of patients [1].

That 7% is a single figure covering the entire treatment period. The label does not break it down by month, by dose step or by how long the burping lasted in the people who had it.

Discontinuation for any adverse reaction was 6.8% on Wegovy versus 3.2% on placebo, and the most common reasons were nausea (1.8% vs 0.2%), vomiting (1.2% vs 0%) and diarrhea (0.7% vs 0.1%) [1].

The dates that are documented: the dose steps

The only part of this story with dates attached is the dosing schedule. Wegovy injection starts at 0.25 mg once weekly for 4 weeks and titrates every 4 weeks: 0.5 mg for weeks 5 through 8, 1 mg for weeks 9 through 12, 1.7 mg for weeks 13 through 16, then maintenance from week 17 [1]. The recommended maintenance dose is 2.4 mg weekly; adults who tolerate 2.4 mg for at least 4 weeks and need more weight loss may move to a maximum of 7.2 mg weekly [1].

These are calendar landmarks only; the label does not tie burping to any of these steps [1].

How fast the stomach empties: what was measured

The label states that Wegovy delays gastric emptying and may affect absorption of oral medicines [1]. A direct measurement comes from a randomized, double-blind, placebo-controlled crossover trial of 30 people with obesity, in which semaglutide was dose-escalated to 1.0 mg weekly. After 12 weeks, gastric emptying in the first hour after a standardized meal was delayed with semaglutide (estimated treatment ratio 0.73, 95% CI 0.61 to 0.87), while emptying measured over 5 hours was not statistically different from placebo [2]. That trial used 1.0 mg, not 2.4 mg, and it did not look at burping.

What the label flags

• Severe gastrointestinal reactions were reported in 4.1% of adults on Wegovy injection versus 0.9% on placebo, and the label says Wegovy is not recommended in patients with severe gastroparesis [1].
• Postmarketing reports listed in the label include ileus, intestinal obstruction and severe constipation with fecal impaction [1].
• For pancreatitis, the label says to discontinue Wegovy if pancreatitis is suspected, and describes persistent or severe abdominal pain, sometimes radiating to the back, which may or may not come with nausea or vomiting [1].
• Gallbladder disease is more frequent on Wegovy: cholelithiasis 1.6% vs 0.7% and cholecystitis 0.6% vs 0.2% in the adult injection trials [1].
• Taken together, any gastrointestinal reaction was reported by 73% of adults on Wegovy versus 47% on placebo [1].